Passage BIO, Inc. (PASG): Nasdaq/NYSE listing notice — Passage Bio receives Nasdaq delisting notice for bid price below $1.00

Passage BIO, Inc.

Notice received Aug 31, 2023; closing bid price below $1/share for 30 consecutive days.
Initial compliance period through Feb 27, 2024; stock must close at $1+ for 10 days.
Company may transfer to Nasdaq Capital Market for additional 180-day grace period.
No decision on response has been made; compliance not assured.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Passage BIO, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

August 31, 2023, Passage Bio, Inc. (the “ Company ”) received notice (the “ Notice ”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“ Nasdaq ”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market. Pursuant to Nasda

View on SEC.gov

Browse all listing & compliance notices →

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-097755

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.